Can Ozempic and Wegovy Slow Aging? A Doctor Reads the New Research

Can weight-loss drugs slow down aging?

I would say possibly, but we are very early. There is exciting research for sure, a lot of it. We have to be careful how we interpret, because we’re acting on processes like chronic inflammation, visceral fat, and insulin resistance in general, which drive a lot of aging. By treating those processes, we are treating the processes that drive aging.

That’s not quite the same thing as saying that the medicine itself is literally an anti-aging medicine. More accurately, it’s a medicine that treats conditions that heavily contribute to aging.

Very encouraging research, and it’s still too early to say yes definitively, but we do know it’s greatly impacting several processes linked to aging.

Can they really slow biological aging?

There is growing research. We don’t have enough evidence to show a causal relationship, but it’s being investigated.

The closest human data so far: in a 2026 trial of 84 adults with HIV, semaglutide slowed several epigenetic aging clocks compared with placebo, including about 9% on one measure. It was an exploratory analysis in a small, specific group.^[1]

What the mouse study found

This is a fascinating study. They took 20-month-old non-obese mice, gave them semaglutide, and continued it for life. The median lifespan rose 12%.^[2] It’s extremely encouraging.

Obviously, this is a preclinical study in mice, not humans. What’s very interesting here is that the mice were not obese or diabetic, so it starts to suggest that there’s some mechanism here that can help people even if they’re not overweight.

I want to be careful. I don’t want to overpromise things. This is a first step, but it’s a very encouraging step. It certainly leads to more questions people will want to answer.

The study used female mice. Treated mice lived a median of 834 days, against 742 days for untreated mice.^[2]

Is it the weight loss or the drug itself?

It’s fairly well established that caloric restriction can contribute to longevity, so it begs the question: did the medicine itself contribute to anti-aging or longevity, or was it an indirect benefit of caloric restriction?

I would say probably both, but again, early research, small studies, preclinical. But what we did see is that even when calories were matched, the semaglutide mice and the dieting mice lost the same weight. Still, the semaglutide mice had other improvements in working memory and blood sugar control.^[2] That suggests that there is benefit beyond strict caloric deficit.

Now, how much, we don’t yet know enough to quantify that, and the mechanism of action, we don’t know enough. This is the first step, but it’s an extremely encouraging first step.

Could GLP-1s protect the heart, kidneys and brain?

I think some early signs are very suggestive of that, particularly heart and kidneys. There’s a growing body of evidence. We have trials showing decreased heart attacks, decreased strokes, decreased cardiovascular deaths, and greatly decreased kidney decline in diabetic patients.^[3][4] I think there’s already significant evidence that these things are protective for the organs.

With the brain, we don’t yet have the same level of research. The two large trials looking at Alzheimer’s disease did not show slowing at this point, which doesn’t disprove that it’s beneficial; it may just mean more research is needed.^[5]

I think it is certainly plausible that the other increases in overall health and wellness will greatly improve people’s brain function and brain health. Decreased chronic inflammation, if nothing else, will greatly impact people’s emotional state, their mood, really their whole body. As we continue to learn more, it’s extremely likely they’ll find more and more improvements for other organs.

Are there particular benefits for women over 50?

I would say absolutely, for a couple of reasons. After menopause, women gain fat, and it tends to be visceral fat. They have a risk of becoming more insulin resistant, and they have increased cardiovascular risks. And those are essentially three things that GLP-1s do. They reduce visceral fat, and they decrease insulin resistance and cardiovascular risk. Extremely beneficial for women in particular.

Now there is a flipside. With decreased caloric intake, there is a risk of muscle loss, and women over 50 are also at risk, so they need strength training. They need extra attention to make sure they’re getting enough protein so they’re not at risk for muscle loss and bone loss. Based on the studies, we recommend eating between 0.8 and 1 gram of protein per pound of body weight per day to reduce muscle loss.^[6][7]

See also: GLP-1s and menopause.

What are the long-term side effects of Ozempic?

Muscle and bone loss are, without a doubt, the biggest risks. These things also compound as we get older. It’s a double whammy.

Obviously, gastrointestinal side effects are an issue. There is a risk of some gallbladder problems, and then there’s a lower risk of pancreatitis, but in my opinion the biggest long-term risk is the muscle and bone loss.

It is something that is addressable and treatable and even preventable, but people need to be educated that protein is critically important, and exercise, particularly resistance training, is particularly important. Now, when I say resistance training, that doesn’t have to mean heavy weights. It can mean resistance bands. It can even mean body weight exercises. People can maintain muscle with forms of yoga and Pilates.

I do think there are some particular benefits to heavier resistance training, but all forms of exercise are beneficial, so I would much rather people do anything they like versus nothing at all.

More from Dr. Snipes: how to keep muscle on a GLP-1. For nausea, a provider can add ondansetron.

Should you take a GLP-1 for longevity?

I would say not yet, but it’s building. We don’t have any human studies looking at longevity as the specific target, but we do have some early preclinical studies that are starting to evaluate longevity as the endpoint.

I do think that we should continue to prescribe them as we’re doing now: obesity, diabetes, cardiovascular risk, and any anti-aging benefit is right now a bonus.

Do I think that may come in the future? Yes. I think it’s very plausible that as we continue to get more and more data, we’ll get to the point where we can justify and really make a case that these medicines can be used for longevity in addition to weight loss.

Will weight-loss injections become part of anti-aging medicine?

Informally, they already are, and I think that will continue to increase as we get more data. It’s not a big jump to say we can use these things to prevent possible metabolic risks in the future. Right now, we certainly use them for people who have diabetes, but what about people who are at high risk of diabetes?

Again, the research is growing, but I think it will definitely become a bigger part of our anti-aging toolbox in the future.

How to get semaglutide or tirzepatide

Compounded semaglutide and tirzepatide need a prescription; each also comes as a microdose (semaglutide, tirzepatide). At Rx Peps Direct, a licensed provider reviews your history for a $39 medical review per order, covering up to three peptides, and sets the dose. If approved, a licensed U.S. 503A pharmacy prepares it and bills the medication at wholesale, in 28 states plus Washington, DC. Tirzepatide is available in 30-day supplies at most. Browse weight-loss medications or compare semaglutide vs tirzepatide.

This article is for education and is not medical advice. Compounded semaglutide and tirzepatide are not FDA approved, and no GLP-1 is approved to slow aging.

Sources

1. Corley MJ, et al. Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. Nat Commun. 2026;17. doi.org/10.1038/s41467-026-72861-3
2. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. 2026;657:469-476. doi.org/10.1038/s41586-026-10940-7
3. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. doi.org/10.1056/NEJMoa2307563
4. Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. doi.org/10.1056/NEJMoa2403347
5. Cummings JL, et al. Efficacy and safety of oral semaglutide in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. 2026;407(10544):2167-2179. doi.org/10.1016/S0140-6736(26)00459-9
6. Morton RW, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. Br J Sports Med. 2018;52(6):376-384. doi.org/10.1136/bjsports-2017-097608
7. Longland TM, et al. Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss: a randomized trial. Am J Clin Nutr. 2016;103(3):738-746. doi.org/10.3945/ajcn.115.119339